I kept the app for the lessons even after I stopped using it for prescriptions
The figure 25.3 % surpasses: Tirzepatide SURMOUNT-1: 22.5 % Semaglutide STEP-1: 14.9 % Retatrutide Phase 2: 24.2 % (comparable, but Phase 3 results for Retatrutide are still lacking) It raises the question whether CagriSema will be the first molecule with an effect truly comparable to bariatric surgery (typically 2530 % reduction)
Secondary Research (Indicative List) Primary Research To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders
Given these benefits, GLP-1s are a powerful tool in the fight against obesity and metabolic dysfunction and have revolutionized treatments
Safety of Semaglutide Smits MM, Van Raalte DH